Autoregulatory domains found within kinases may provide more unique targets for chemical
inhibitors than the conserved ATP-binding pocket targeted by most inhibitors. The kinase …

Cancer drug development is leading the way in exploiting molecular biological and genetic
information to develop'personalized'medicine. The new paradigm is to develop agents that …

Leucine-rich repeat kinase 2 (LRRK2) is a multifunctional protein that orchestrates a diverse
array of cellular processes, including vesicle transport, autophagy, lysosome degradation …

We examined in vivo FLT3 inhibition in acute myeloid leukemia patients treated with
chemotherapy followed by the FLT3 inhibitor lestaurtinib, comparing newly diagnosed acute …

Visceral leishmaniasis causes considerable mortality and morbidity in many parts of the
world. There is an urgent need for the development of new, effective treatments for this …

Sixteen novel quinazoline-based derivatives were designed and synthesized via
modification of the VEGFR-2 reported inhibitor 7 in order to increase the binding affinity of …

The human FGF receptors (FGFRs) play critical roles in various human cancers, and several
FGFR inhibitors are currently under clinical investigation. Resistance usually results from …

At the root of the so-called precision medicine or precision oncology, which is our focus
here, is the hypothesis that cancer treatment would be considerably better if therapies were …

Inhibiting VEGFR-2 has been set up as a therapeutic strategy for treatment of cancer.
Accordingly, new quinazoline-based derivatives having the structural features of VEGFR-2 …

Protein kinases play a pivotal role in cell signaling, and dysregulation of many kinases has
been linked to disease development. A large number of kinase inhibitors are therefore …